BR100 Decreased By (-0.09%)
BR30 Decreased By (-0.08%)
KSE100 Decreased By (-0.03%)
KSE30 Decreased By (-0.09%)
AGHA 7.73 Decreased By ▼ -0.08 (-1.02%)
BECO 5.19 Decreased By ▼ -0.02 (-0.38%)
BML 57.50 No Change ▼ 0.00 (0%)
BOP 33.88 Decreased By ▼ -0.15 (-0.44%)
CNERGY 10.01 Increased By ▲ 0.05 (0.5%)
CSIL 5.32 Increased By ▲ 0.01 (0.19%)
FCCL 54.40 Decreased By ▼ -0.30 (-0.55%)
FFL 16.75 Increased By ▲ 0.06 (0.36%)
FNEL 1.25 Increased By ▲ 0.02 (1.63%)
KEL 7.38 Decreased By ▼ -0.02 (-0.27%)
KOSM 5.70 Decreased By ▼ -0.07 (-1.21%)
LOTCHEM 29.20 Decreased By ▼ -0.12 (-0.41%)
MLCF 93.80 Decreased By ▼ -0.56 (-0.59%)
NBP 203.00 Decreased By ▼ -0.05 (-0.02%)
NCPL 56.80 Decreased By ▼ -0.20 (-0.35%)
NPL 67.75 Increased By ▲ 0.05 (0.07%)
OGDC 316.57 Increased By ▲ 0.73 (0.23%)
PACE 10.68 Increased By ▲ 0.04 (0.38%)
PAEL 43.19 Decreased By ▼ -0.01 (-0.02%)
PIBTL 16.64 Decreased By ▼ -0.10 (-0.6%)
PPL 218.51 Decreased By ▼ -1.27 (-0.58%)
PRL 50.01 Increased By ▲ 0.82 (1.67%)
PTC 71.00 Increased By ▲ 0.47 (0.67%)
SSGC 27.93 Decreased By ▼ -0.32 (-1.13%)
TBL 9.81 Decreased By ▼ -0.05 (-0.51%)
TELE 8.71 Decreased By ▼ -0.08 (-0.91%)
TPL 18.25 Increased By ▲ 0.01 (0.05%)
TPLP 13.46 Increased By ▲ 0.19 (1.43%)
TREET 22.70 Decreased By ▼ -0.02 (-0.09%)
TRG 60.51 Increased By ▲ 0.37 (0.62%)
Business & Finance

Pfizer to pursue bringing COVID-19 vaccine to India after import relaxation

  • "We have noted the recent announcement with regard to the regulatory pathway for global vaccines," a Pfizer spokesperson told Reuters in an email.
  • "We remain committed to continuing our engagement with the government towards making the Pfizer and BioNTech vaccine available for use in the government's immunisation program."
Published Updated
By

NEW DELHI: Pfizer Inc said on Tuesday it would work towards bringing the COVID-19 vaccine it developed with Germany's BioNTech to India after the government eased import rules, after withdrawing its application in February.

"We have noted the recent announcement with regard to the regulatory pathway for global vaccines," a Pfizer spokesperson told Reuters in an email.

"We remain committed to continuing our engagement with the government towards making the Pfizer and BioNTech vaccine available for use in the government's immunisation program."

Comments

Comments are closed for this article.